伊犁川宁生物技术股份有限公司 独立董事关于第二届董事会第四次会议 相关事项的事前认可意见 根据《上市公司治理准则》《上市公司独立董事管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等法律、法规和规范性文件及《公司章程》的相关规定， 我们作为伊犁川宁生物技术股份有限公司（以下简称"公司"）的独立董事，本 着独立审慎、实事求是的原则，召开了独立董事专门会议，就公司第二届董事会 第四次会议的相关事项进行了认真审议，并发表事前认可意见如下： 一、关于预计公司 2024 年度日常关联交易情况的事前认可意见 HFI V 曹亚丽: 高献礼: 2023 年 12 月 7 日 (本页无正文,为《伊犁川宁生物技术股份有限公司独立董事关于第二届董 事会第四次会议相关事项的事前认可意见》之签字页) 独立董事: 段完 段 宏: 经核查，公司预计 2024 年度日常关联交易情况符合公司正常经营活动所需， 是基于公司与合作方的正常业务往来，交易价格为市场公允价格，不存在损害公 司及股东特别是中小股东利益的情形，不会对公司独立性产生影响，不存在通过 上述关联交易转移 ...

伊犁川宁生物技术股份有限公司 章 程 公司系由伊犁川宁生物技术有限公司于 2020 年 6 月依法整体变更设立， 并在伊宁市市场监督管理局注册登记，取得企业法人营业执照，营业执照号码 91654002564379263N。 第三条 公司于 2022 年 10 月 25 日经中国证券监督管理委员会（以下简 称"中国证监会"）同意注册，首次向社会公众发行人民币普通股 22,280 万 股，并于 2022 年 12 月 27 日在深圳证券交易所上市。 第四条 公司名称：伊犁川宁生物技术股份有限公司 二〇二三年十二月 | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 3 | | | 第二节 | 股份增减和回购 4 | | | 第三节 | 股份转让 6 | | | 第四章 | 股东和股东大会 | 6 | | 第一节 | 股东 6 | | | 第二节 | 股东大会的一般规定 9 | | | 第三节 | 股东大会的召集 11 | | | 第四节 | 股东大会的提案与通知 12 | | | 第五节 ...

证券代码：301301 证券简称：川宁生物 伊犁川宁生物技术股份有限公司投资者关系活动记录表 编号：0007 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩交流会 投资者关系 ☐新闻发布会 ☐路演活动 活动类别 ☐现场参观 ☐业绩说明会 ☐其他： 东方资本、明世伙伴、睿柏资本、明达资产、征金资本、The Carlyle Group、华泰证券、中国守正基金、富安达基金、红筹投 资、宏利投资、幸福人寿、东海证券、民生信托、长盛基金、 金信基金、汇升投资、中金公司、中信期货、华安基金、光大 证券、博远基金、华夏基金、景泰利丰、信达澳亚基金、人寿 资产、富国基金、中银国际证券、聚鸣投资、融通基金、远海 资产、英大资产、丹羿投资、中信资管、人保、阳光资产、民 生证券、首创证券、宁银理财、天风证券、中信建投、中信证 参与单位名称 券、远信投资、紫阁投资、浙商证券、泰达宏利基金、国金证 及人员姓名 券、首钢基金、国盛证券、银河证券、信达证券、兴业证券、 长信基金、昆仑资本、沣杨资产、新活力资本、东吴证券、西 南证券、西部证券、平安银行、华融基金、建信养老金、涌容 ...

Financial Performance - The company's revenue for Q3 2023 reached ¥1,164,134,161.57, representing a year-over-year increase of 21.81%[4] - Net profit attributable to shareholders for the same period was ¥249,281,110.49, a significant increase of 162.02% compared to the previous year[4] - Basic earnings per share for Q3 2023 was ¥0.11, up 120.00% year-over-year[4] - Total operating revenue for the third quarter of 2023 reached ¥3,581,333,354.27, an increase of 21.8% compared to ¥2,939,569,616.72 in the same period last year[21] - The company's net profit attributable to shareholders increased to ¥1,111,638,036.84 from ¥678,208,636.83, marking a growth of 63.9%[20] - Net profit attributable to the parent company shareholders reached ¥640,149,778.46, up from ¥332,291,748.85, reflecting a growth of 92.7%[23] - Total operating profit rose to ¥776,737,673.12 compared to ¥433,774,118.84, an increase of 79.1%[22] - Revenue from sales of goods and services amounted to ¥2,812,201,611.49, compared to ¥1,648,417,428.65, marking an increase of 70.4%[24] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥1,102,683,880.83, showing a remarkable increase of 1,162.65%[4] - The net cash flow from operating activities reached ¥1,102,683,880.83, a significant increase of 1,162.65% compared to the same period last year, primarily due to increased revenue and improved collections[10] - Cash flow from operating activities generated ¥1,102,683,880.83, a significant recovery from a negative cash flow of -¥103,767,634.93 in the previous period[25] - The company recorded a net cash outflow from financing activities of ¥1,505,186,874.57, compared to a net outflow of ¥79,248,454.35 in the previous period[26] - The net cash flow from investing activities was -¥204,973,163.94, reflecting a 313.77% increase in investment amounts for fundraising projects compared to the previous year[10] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,042,128,190.04, a decrease of 3.35% from the end of the previous year[4] - Total assets as of September 30, 2023, were ¥10,042,128,190.04, down from ¥10,390,399,359.24, indicating a decrease of 3.4%[20] - Total liabilities decreased to ¥3,379,210,649.96 from ¥4,179,912,376.97, a decline of 19.2%[19] - The company’s long-term borrowings decreased by 51.52% to ¥692,333,333.00, primarily due to repayment of long-term loans[8] Equity and Shareholder Information - The company’s total equity attributable to shareholders increased by 7.21% to ¥6,652,047,006.74 compared to the previous year[4] - The total number of ordinary shareholders at the end of the reporting period was 41,497, with Sichuan Kelun Pharmaceutical Co., Ltd. holding 70.63% of shares[12] - The top ten shareholders collectively hold significant stakes, with the largest shareholder owning 1,569,887,643 shares[12] - The company has no newly added restricted shares during the reporting period, maintaining a total of 2,000,000,000 restricted shares[15] - The company plans to lift restrictions on certain shares on December 27, 2023, and December 27, 2025, for various shareholders[14] Research and Development - The company reported a significant increase in research and development expenses, totaling ¥39,057,245.56, which is a 47.89% increase compared to the previous year[9] - Research and development expenses for the quarter were ¥39,057,245.56, compared to ¥26,409,007.12 in the previous year, reflecting a year-over-year increase of 47.8%[21] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[15] Inventory and Receivables - The company experienced a 36.63% decrease in inventory, amounting to ¥876,817,989.56, due to seasonal procurement and production usage[7] - Inventory decreased significantly to ¥876,817,989.56 from ¥1,383,634,677.19, a reduction of 36.6%[19] - Accounts receivable increased to ¥906,999,094.69 from ¥877,597,384.20, representing a growth of 3.7%[18] Financial Expenses and Income - The company’s financial expenses decreased by 51.00% to ¥44,149,663.59, attributed to reduced interest expenses and increased exchange gains[9] - Interest income increased to ¥12,506,244.26 from ¥3,888,496.79, representing a growth of 221.5%[22] Overall Financial Health - The financial report indicates a strong recovery in cash flow from operations, suggesting improved operational efficiency and market demand[10] - The company continues to monitor its investment strategies closely, particularly in light of the significant increase in cash outflows for investment activities[10] - The company recorded a total comprehensive income of ¥640,149,589.72, up from ¥332,291,056.73, indicating a growth of 92.7%[23] - Cash and cash equivalents at the end of the period totaled ¥1,029,201,761.89, compared to ¥282,930,884.36, showing a significant increase[26] - The company's cash and cash equivalents decreased to ¥1,102,122,500.23 from ¥1,632,031,476.79, a decline of 32.4%[18]

证券代码：301301 证券简称：川宁生物 公告编号：2023-052 伊犁川宁生物技术股份有限公司 第二届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 伊犁川宁生物技术股份有限公司（以下简称"公司"）第二届监事会第三次 会议通知和材料于 2023 年 10 月 10 日以专人送达、电子邮件的方式发出，会议 于 2023 年 10 月 20 日上午 11 点在公司会议室以现场表决方式召开。会议由监事 会主席杨帆先生主持，公司应出席监事 3 人，实际出席监事 3 人。本次会议的召 集和召开程序符合《中华人民共和国公司法》等有关法律、行政法规、部门规章、 规范性文件和《公司章程》的相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事认真审议，以书面记名投票表决方式通过以下决议： （一）以 3 票同意，0 票反对，0 票弃权，审议通过了《关于审议公司 2023 年第三季度报告的议案》 监事会对公司 2023 年第三季度报告全文进行了认真严格的审核，认为公司 2023 年第三季度报告的编制和审议程 ...

证券代码：301301 证券简称：川宁生物 公告编号：2023-051 伊犁川宁生物技术股份有限公司 经与会董事认真审议，以书面记名投票表决方式通过以下决议： （一）以 7 票同意，0 票反对，0 票弃权，审议通过了《关于审议公司 2023 年第三季度报告的议案》 董事会认真审阅了《伊犁川宁生物技术股份有限公司 2023 年第三季度报告》， 认为公司 2023 年第三季度报告的编制要求和审批程序均符合法律、行政法规以 及中国证监会的有关规定，公允反映了公司 2023 年 9 月 30 日的财务状况以及 2023 年 1 月至 9 月的经营成果和现金流量，保证公司 2023 年第三季度报告内容 真实、准确、完整，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容详见公司信息披露指定网站巨潮资讯网（www.cninfo.com.cn）上的 《伊犁川宁生物技术股份有限公司 2023 年第三季度报告》。 第二届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 伊犁川宁生物技术股份有限公司（以下简称"公司"）第二届董事会 ...

证券代码：301301 证券简称：川宁生物 伊犁川宁生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |--------------|-------------------------|-------------------------|---------------------------------------| | | ☐特定对象调研 | ☐分析师会议 | | | 投资者关系 | ☐媒体采访 | 业绩交流会 | | | 活动类别 | ☐新闻发布会 | ☐路演活动 | | | | ☐现场参观 | ☐业绩说明会 | | | | ☐其他： | | | | | | | | | | | | | | | | | | | 参与单位名称 | | | | | 及人员姓名 | 资 、 泰康 养老 | 、碧 云 资本 Greencourt | 、 China Alpha Fund | | | Management (HK) Limited | 、 纽富斯投资 | 、 Xingtai Capital | | | Management Limited | 、高盛、 | Allianz ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥2,417,199,192.70, representing a 21.84% increase compared to ¥1,983,863,175.58 in the same period last year[10]. - Net profit attributable to shareholders was ¥390,868,667.97, a significant increase of 64.82% from ¥237,153,026.36 in the previous year[10]. - The net cash flow from operating activities surged to ¥1,036,235,791.88, marking an increase of 1,636.08% compared to ¥59,688,116.96 in the same period last year[10]. - Basic and diluted earnings per share both increased by 50.00%, reaching ¥0.18 compared to ¥0.12 in the previous year[10]. - The weighted average return on net assets rose to 6.11%, up from 4.85% in the previous year[10]. - The company reported a net profit for the first half of 2023 of CNY 475,357,061.84, compared to CNY 279,919,282.08 in the previous year, indicating significant growth[154]. - The total comprehensive income for the first half of 2023 was approximately CNY 390.87 million, reflecting a significant increase compared to the previous period[165]. Assets and Liabilities - Total assets at the end of the reporting period were ¥9,761,444,545.93, a decrease of 6.05% from ¥10,390,399,359.24 at the end of the previous year[10]. - The company's total assets amounted to CNY 9,459,458,368.24, down from CNY 10,383,592,982.77 at the beginning of the year, a decrease of 8.9%[152]. - Total liabilities decreased to CNY 3,361,336,304.27 from CNY 4,179,912,376.97, indicating a decline of approximately 19.6%[149]. - Long-term borrowings were reduced to CNY 692,333,333.00 from CNY 1,428,000,000.00, a decrease of about 51.5%[149]. - The company's equity attributable to shareholders increased to CNY 6,394,106,519.70 from CNY 6,204,485,260.20, reflecting an increase of approximately 3.1%[149]. Research and Development - The company has established a large-scale industrial production system in the antibiotic intermediate sector, leading the domestic and global market with significant production of key intermediates[18]. - The company’s subsidiary, Ruikang Biotechnology, focuses on synthetic biology technologies, aiming to develop high-value natural products and advanced cosmetic raw materials[19]. - The company has developed 5 types of high-quality chassis strains, including E. coli, yeast, and Streptomyces, focusing on high-value natural health products and biopesticides[23]. - The innovative R&D model employs a "design-build-test-learn" (DBTL) loop, significantly enhancing the efficiency of industrial strain development compared to traditional methods[22]. - The company is actively developing new products and technologies in synthetic biology to maintain market competitiveness and profitability[82]. Environmental Initiatives - The company is committed to complying with various environmental protection laws and standards, ensuring minimal negative impact on the ecological environment during production[92]. - The company has established a comprehensive waste treatment facility to ensure compliance with environmental standards[92]. - The company has implemented various environmental management systems to ensure compliance with environmental protection responsibilities[93]. - The company has established a greenhouse gas emission management system to enhance carbon emission control and management, aligning with national carbon neutrality goals[102]. - The company has invested CNY 265.34 million in environmental protection facilities operation costs during the reporting period[99]. Market Strategy and Operations - The company has maintained a stable competitive landscape in the antibiotic intermediate industry, with market demand remaining robust and product prices gradually increasing[18]. - The company has implemented a marketing strategy centered around key customers, enhancing service quality and expanding sales channels, including the establishment of two sales agents for cosmetic raw materials[38]. - The company maintains a direct sales model for domestic sales and a combination of direct and indirect sales for international markets, adjusting product pricing based on raw material costs and competitor pricing[31]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[154]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[2]. - The company has established a long-term incentive system, granting 11.8 million restricted stock options at a price of CNY 4.74 per share to 38 eligible employees, with 9.09 million shares (77.03%) allocated to 18 core R&D personnel[39]. - The company has committed to not transferring or entrusting others to manage its shares for 36 months from the date of its initial public offering[106]. - The company has reported normal compliance with all commitments made[108]. - The company has established a plan for shareholder dividend returns, which will be considered by the board and shareholders, taking into account the opinions of independent directors and public investors[109]. Risks and Challenges - The company faces macroeconomic risks, including inflation and geopolitical tensions, which could negatively impact demand for its products[78]. - The company is exposed to raw material price fluctuations, particularly for corn and soybean products, which could affect its gross margin[80]. - The company is addressing intensified market competition by focusing on R&D investment and maintaining product quality to sustain its competitive edge[79]. Compliance and Legal Matters - The semi-annual financial report has not been audited[120]. - The company did not experience any major litigation or arbitration matters during the reporting period[121]. - There were no significant penalties or rectification situations reported[122]. - The company has maintained a good integrity status with no issues reported for itself or its controlling shareholders[122].

长江证券承销保荐有限公司 关于伊犁川宁生物技术股份有限公司 2023 年度持续督导定期现场检查报告 保荐机构名称：长江证券承销保荐有限公 司 被保荐公司简称：川宁生物（301301） 保荐代表人姓名：李忠 联系电话：010-66220588 保荐代表人姓名：李振东 联系电话：010-57065264 现场检查人员姓名：李忠 现场检查对应期间：2022 年 12 月至 2023 年 6 月 现场检查时间：2023.8.1 至 2023.8.9 一、现场检查事项 现场检查意见 （一）公司治理 是 否 不适用 现场检查手段：（1）查阅公司章程及各项规章制度；（2）查阅"三会"文件，包括会议通 知、签到表、会议决议、会议记录、公告等；（3）实地查看公司主要生产经营场所，了解 公司治理及独立性情况；（5）访谈公司相关人员，了解公司基本制度的执行情况，了解公 司董事、监事和高级管理人员履行职务勤勉尽责情况及变动情况，了解控股股东、实际控制 人遵守相关承诺的情况。 1.公司章程和公司治理制度是否完备、合规 √ 2.公司章程和三会规则是否得到有效执行 √ 3.三会会议记录是否完整，时间、地点、出席人员及会议 内容等要件是否齐 ...

证券代码：301301 证券简称：川宁生物 公告编号：2023-049 伊犁川宁生物技术股份有限公司 关于调整公司董事会第二届审计委员会成员构成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（以下简称"公司"）于 2023 年 8 月 18 日 召开第二届董事会第二次会议，审议通过了《关于调整公司董事会第二届审计委 员会成员构成的议案》。为完善公司治理结构，保证公司董事会专门委员会规范 运作，充分发挥独立董事在上市公司治理中的作用，根据《中华人民共和国公司 法》《中华人民共和国证券法》等法律法规、规范性文件的相关规定，公司董事 会对审计委员会成员进行调整，公司董事、总经理邓旭衡先生辞去审计委员会委 员职务，董事会选举独立董事高献礼先生担任审计委员会委员。调整后的董事会 审计委员会由段宏女士、曹亚丽女士、高献礼先生 3 位独立董事担任委员，其中 段宏女士担任主任委员。 以上委员任期自相关董事会会议审议通过之日起至公司第二届董事会成员 任期届满，其职责权限、决策程序和议事规则均按照《公司章程》和董事会专门 委员会工作细则执行。 ...